Viking Therapeutics (VKTX) Fundamental Analysis: Revenue, Earnings & Valuation

6.70 / 10

Outperform

Fundamental score is 6.7/10 (Outperform). Strong points include high accounts‑receivable turnover, interest coverage, asset‑MV, revenue‑MV and inventory turnover. Weaknesses are low fixed‑asset turnover, high income‑tax ratio and modest PB‑ROE, tempering the upside.

Analysis Checks(7/10)

Revenue-MV

Value-0.08

Score3/3

Weight39.11%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight2.08%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.22%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.20%

1M Return-0.65%

PB-ROE

Value4.45

Score0/3

Weight16.08%

1M Return3.80%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-5.00%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-4.12%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.48%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.44%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight61.19%

1M Return13.09%

Is VKTX fundamentally strong?

VKTX scores 6.70/10 on fundamentals and holds a Discounted valuation at present. Backed by its -47.34% ROE, 0.00% net margin, -10.69 P/E ratio, 6.01 P/B ratio, and -215.84% earnings growth, these metrics solidify its Outperform investment rating.